We are live on ! Find out more
VIRS

Pacer BioThreat Strategy ETF
VIRS

Delisted

VIRS was delisted on the 10th of October, 2024.

Back to rankings

4 hedge funds and large institutions have $2.32M invested in Pacer BioThreat Strategy ETF in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

1% less capital invested

Capital invested by funds: $2.35M → $2.32M (-$35K)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$529K
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$28

Top Sellers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$206K
2
Osaic Holdings
Osaic Holdings
Arizona
-$24.2K
3
UBS Group
UBS Group
Switzerland
-$57
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
1
Osaic Holdings
Arizona
$1.59M -$24.2K -849 -1%
Royal Bank of Canada
2
Royal Bank of Canada
Ontario, Canada
$712K +$529K +18,577 +227%
UBS Group
3
UBS Group
Switzerland
$12K -$57 -2 -0.4%
Cambridge Investment Research Advisors
4
Cambridge Investment Research Advisors
Iowa
– -$206K -6,655 Closed
Fidelity Investments
5
Fidelity Investments
Massachusetts
– +$28 +1 New

VIRS Hedge Fund Activity: Q2 2022 in Review

4 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Pacer BioThreat Strategy ETF (VIRS) for Q2 2022, worth a combined $2.32M — down 1.5% from $2.35M a quarter earlier.

Fund positioning in VIRS was balanced in Q2 2022: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was Royal Bank of Canada, adding an estimated $529K. The largest seller was Cambridge Investment Research Advisors, exiting entirely with an estimated $206K sold.

  • 4 institutional investors held Pacer BioThreat Strategy ETF (VIRS) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $2.32M of Pacer BioThreat Strategy ETF stock for Q2 2022, down 1.5% quarter-over-quarter.
  • 1 fund opened new Pacer BioThreat Strategy ETF positions in Q2 2022 and 1 closed out, a net change of 0 holders.
  • The largest Pacer BioThreat Strategy ETF buyer in Q2 2022 was Royal Bank of Canada, an estimated $529K added.
  • The largest Pacer BioThreat Strategy ETF seller in Q2 2022 was Cambridge Investment Research Advisors, an estimated $206K sold.

Based on aggregated 13F filings for Q2 2022.